Literature DB >> 17497212

Immunization of DNA vaccine encoding C3d-VP1 fusion enhanced protective immune response against foot-and-mouth disease virus.

Huiying Fan1, Tiezhu Tong, Huanchun Chen, Aizhen Guo.   

Abstract

Because foot-and-mouth disease virus (FMDV) remains a great problem to many livestock of agricultural importance, safe, effective vaccines are in great need. DNA vaccine would be a promising candidate but the design remains to be optimized. VP1 gene of FMDV strain O/ES/2001 was linked to three copies of either porcine or murine C3d or four copies of a 28-aa fragment of murine C3d containing the CR2 receptor binding domain (M28). The resultant plasmids encoding C3d/M28-VP1 fusion or only VP1 as control were immunized guinea pigs. Both cellular and humoral immune responses were evaluated and protection was observed after virus challenge. As a result, although the plasmid encoding only VP1 could elicit virus-binding antibody detected by ELISA, splenocyte proliferation, IL-4 and IFN-gamma production, the levels were significantly less than C3d/M28-VP1 fusion. Furthermore, VP1 failed to induce neutralization antibody and protect animals against virus challenge, while murine C3d-VP1 fusion efficiently induced neutralization antibody response and provided 87.50% of the animals with complete protection and 12.50% with partial protection. Among murine C3d, M28, and porcine C3d, the adjuvant effect of murine C3d is strongest, followed by porcine C3d, and last murine M28. In conclusion, the fact that C3d genes, when coupled to VP1 gene, are able to greatly enhance the protective immune response of VP1 DNA in guinea pigs suggests that C3d-VP1 DNA chimera has a significant potential for use as a novel DNA vaccine against FMDV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17497212     DOI: 10.1007/s11262-007-0105-0

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  44 in total

1.  An immunoglobulin G based chimeric protein induced foot-and-mouth disease specific immune response in swine.

Authors:  E W Chan; H T Wong; S C Cheng; W Y Yan; Z X Zheng; Z T Sheng; L Q Zhu; Y Xie
Journal:  Vaccine       Date:  2000-10-15       Impact factor: 3.641

2.  Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences.

Authors:  Z Li; A Howard; C Kelley; G Delogu; F Collins; S Morris
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Identification of T-cell epitopes in nonstructural proteins of foot-and-mouth disease virus.

Authors:  E Blanco; M Garcia-Briones; A Sanz-Parra; P Gomes; E De Oliveira; M L Valero; D Andreu; V Ley; F Sobrino
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase.

Authors:  Leticia Cedillo-Barrón; Mildred Foster-Cuevas; Graham J Belsham; François Lefèvre; R Michael E Parkhouse
Journal:  J Gen Virol       Date:  2001-07       Impact factor: 3.891

5.  Delineation of a neutralizing subregion within the immunodominant epitope (GH loop) of foot-and-mouth disease virus VP1 which does not contain the RGD motif.

Authors:  F Brown; N Benkirane; D Limal; H Halimi; J F Newman; M H Van Regenmortel; J P Briand; S Muller
Journal:  Vaccine       Date:  1999-08-20       Impact factor: 3.641

6.  Amplification of the antibody response by C3b complexed to antigen through an ester link.

Authors:  M B Villiers; C L Villiers; A M Laharie; P N Marche
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

7.  A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2.

Authors:  Ho Tsun Wong; Samuel Chak-Sum Cheng; Fion Wan-Yee Sin; Ella Wai-Ching Chan; Zu Tian Sheng; Yong Xie
Journal:  Vaccine       Date:  2002-06-21       Impact factor: 3.641

8.  Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.

Authors:  J T Qiu; B Liu; C Tian; G N Pavlakis; X F Yu
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 9.  Complement's participation in acquired immunity.

Authors:  Claus Henrik Nielsen; Robert Graham Quinton Leslie
Journal:  J Leukoc Biol       Date:  2002-08       Impact factor: 4.962

10.  Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.

Authors:  Thomas D Green; David C Montefiori; Ted M Ross
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more
  1 in total

Review 1.  DNA vaccines in veterinary use.

Authors:  Laurel Redding; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2009-09       Impact factor: 5.217

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.